BioTuesdays

Tag - MPH

Medicure

Mackie cuts Medicure PT to $2.80 from $6.50

Mackie Research slashed its price target for Medicure (TSXV:MPH) to $2.80 from $6.50, and maintained a “hold” rating, citing highly lowered revenue estimates. The stock closed at $2.41 on April 15. Analyst Andre Uddin...

Medicure to leverage sales model to new products

By Len Zehr Medicure (TSXV:MPH) intends to leverage its unique sales and marketing model, which has fueled the growth of its Aggrastat IV platelet inhibitor, as it brings new generic products into its cardiovascular...